<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398459</url>
  </required_header>
  <id_info>
    <org_study_id>IHBDH-IIT2020004</org_study_id>
    <nct_id>NCT04398459</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia</brief_title>
  <official_title>A Phase II, Single-Center, Open-label Trial to Determine the Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm study to evaluate the safety and efficacy of Ibrutinib in
      subjects with refractory/relapsed autoimmune hemolytic anemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>within 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and severe adverse events</measure>
    <time_frame>within 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival rate</measure>
    <time_frame>within 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Refractory/Relapsed Autoimmune Hemolytic Anemia</condition>
  <arm_group>
    <arm_group_label>IBRIAN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Each recruited subject will accept Ibrutinib treatment.</description>
    <arm_group_label>IBRIAN</arm_group_label>
    <other_name>BTK inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG â‰¤ 3

          -  Age from 6 to 70.

          -  Diagnosed with WAIHA or MAIHA.

          -  Meets the criteria of relapsed / refractory AIHA.

          -  Meets the criteria of DAT-negative AIHA without any other inherited or acquired
             hemolytic diseases, and previously treated effectively with glucocorticoids and
             rituximab.

          -  Signed informed consent.

          -  Organs in good function.

        Exclusion Criteria:

          -  Nursing woman

          -  Active bacterial, virus, fungal or parasitic infection, including HIV infection, HbsAg
             and HBV DNA positive, HCV DNA positive, etc.

          -  Diagnosed with cold agglutinin disease or cold agglutinin syndrome or paroxysmal cold
             hemoglobinuria.

          -  Secondary AIHA caused by drugs or infection.

          -  Received rituximab in 8 weeks before enrollment.

          -  Previously received treatment with BTK inhibitor.

          -  Previously received organ or stem cell transplantation.

          -  Have a history of thrombosis or organ infarction.

          -  Diagnosed with an active stage of connective tissue disease.

          -  Have a history of lymphoproliferative tumors or any other malignant tumors.

          -  Have other inherited or acquired hemolytic diseases.

          -  Received low-molecular-weight heparin or warfarin within 1 week before enrollment or
             during the Ibrutinib treatment.

          -  Received CYP3A4 Enzyme Inhibitors or Inducers within 1 week before enrollment or
             during the Ibrutinib treatment.

          -  Have a history of mental illness.

          -  Inability to understand or to follow study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Shi, PhD</last_name>
    <phone>(86)2223900913</phone>
    <email>shijun@ihcams.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jingyu Zhao, MPH</last_name>
    <phone>(86)13752253515</phone>
    <email>zhaojingyu@ihcams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regenerative Medicine Center</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Shi, PhD</last_name>
      <phone>(86)2223900913</phone>
      <email>shijun@ihcams.ac.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jingyu Zhao, MPH</last_name>
      <phone>(86)13752253515</phone>
      <email>zhaojingyu@ihcams.ac.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Jun Shi</investigator_full_name>
    <investigator_title>Director, Regenerative Medicine Clinic Center</investigator_title>
  </responsible_party>
  <keyword>Ibrutinib</keyword>
  <keyword>BTK Inhibitor</keyword>
  <keyword>autoimmune hemolytic anemia</keyword>
  <keyword>AIHA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

